Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

Hypercortisolism identified in 27.3 percent of patients with resistant hypertension REDWOOD CITY, Calif. --(BUSINESS WIRE)--Mar. 28, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe